SCHEMBL3752413

SCHEMBL3752413

COc1ccc(C(N)c2ccc(F)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.53
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C19 P33261 2/20 0.48
LMNA P02545 4/20 0.47
HTT P42858 3/20 0.47
MAPK1 P28482 3/20 0.47
MITF O75030 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
GPR35 Q9HC97 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
XBP1 P17861 1/20 0.47
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL114318 0.89 CA1 (0.58) CYP1A2CYP2D6CYP2C19MAPK1NPSR1
SCHEMBL11475903 0.89 CA1 (0.58) CYP1A2CYP2D6CYP2C19MAPK1NPSR1
Ammonia Solution, Strong SCHEMBL6422238 0.87 CYP1A2 (0.55) CYP1A2CYP2D6CYP2C19MAPK1CA12
Hydrochloric Acid SCHEMBL8894706 0.87 CYP1A2 (0.55) CYP1A2CYP2D6CYP2C19MAPK1GAA
SCHEMBL933502 0.82 IDO1 (0.52) CA1CA2CA7CA9MAOA
SCHEMBL7024215 0.82
SCHEMBL8298 0.82
SCHEMBL11965157 0.81 ACHE (0.65) CYP1A2CYP2D6CYP2C19MAPK1CA12
SCHEMBL2153572 0.81 ACP3 (0.56) CYP1A2CYP2D6CYP2C19MAPK1CA12
SCHEMBL19282953 0.81 ACP3 (0.56) CYP1A2CYP2D6CYP2C19MAPK1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350047-B2 Methods of preparing secondary carbinamine compounds with boronic acids THADANI AVINASH N (CA) 2013-01-08 US disclosed
US-8350047-B2 Methods of preparing secondary carbinamine compounds with boronic acids THADANI AVINASH N (CA) 2013-01-08 US disclosed
US-20100298572-A1 METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS PANASONIC CORPORATION (JP) 2010-11-25 US disclosed
US-20100298572-A1 METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS PANASONIC CORPORATION (JP) 2010-11-25 US disclosed
WO-2008119161-A1 METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS KANATA CHEMICAL TECHNOLOGIES INC. (CA) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298572-A1 METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS C9, BCAT2, SLC1A5 NFE2L2 316/4885CYP1A2 541/4885CYP2D6 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.